Science and Technology

Author Archive | xchem-editor

October 1, 2020

Proteros Biostructures and X-Chem to offer Comprehensive Joint Target-to-Lead Drug Discovery Services

Munich, Germany and Waltham, Mass –October 1, 2020 – Proteros Biostructures GmbH (Proteros) and X-Chem, Inc. (X-Chem) announced today the launch of an alliance with the goal of offering Hit-Identification and Target-to-Lead drug discovery services based on their complementary technology platforms. The alliance combines Proteros’ strengths in protein sciences, structural biology (crystallography and CryoEM), and […]

Continue Reading
July 22, 2020

X-Chem Announces Achievement of Milestone In Orexia Collaboration

Waltham, Mass – July 22, 2020 – X-Chem, Inc. (X-Chem), the global leader in DNA-encoded small molecule library screening and drug discovery, announced today that it has met a key development milestone in its collaboration with Orexia Limited (Orexia), a company focused on developing orexin positive modulators using unique structure based drug design capabilities.

Continue Reading
July 21, 2020

J Med Chem Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry

The activity of the secreted phosphodiesterase autotaxin produces the inflammatory signaling molecule LPA and has been associated with a number of human diseases including idiopathic pulmonary fibrosis (IPF). We screened a single DNA-encoded chemical library (DECL) of 225 million compounds and identified a series of potent inhibitors. Optimization of this series led to the discovery […]

Continue Reading
July 21, 2020

J Med Chem Machine Learning on DNA-Encoded Libraries: A New Paradigm for Hit Finding

June 11th 2020|J Med Chem Machine Learning on DNA-Encoded Libraries|A New Paradigm for Hit Finding DNA-encoded small molecule libraries (DELs) have enabled discovery of novel inhibitors for many distinct protein targets of therapeutic value. We demonstrate a new approach applying machine learning to DEL selection data by identifying active molecules from large libraries of commercial […]

Continue Reading
June 11, 2020

Study Published in the Journal of Medicinal Chemistry Demonstrates the Power of Machine Learning to Unlock New Chemistry and Biology to Treat Disease

WALTHAM, Mass. – June 11, 2020 – X-Chem, Inc., the leader in DNA-encoded small molecule library screening, and ZebiAI Therapeutics, a drug discovery company unlocking new disease targets, today announced the publication of a large prospective study to evaluate the power of machine learning (ML) to accelerate and improve the drug discovery process. The study, […]

Continue Reading
June 3, 2020

GHO Capital Acquires X-Chem, the Leading Provider of DNA-Encoded-Library-Mediated Drug Discovery Services

London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, announces the acquisition of X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded Library (DEL)-based discovery services, from an affiliate of The Carlyle Group and Hellman & Friedman LLC.

Continue Reading
May 20, 2020

X-Chem Announces Licensing of a Drug Discovery Program to Otsuka

Waltham, Mass – May 20, 2020 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has licensed a drug discovery program from X-Chem.

Continue Reading
February 6, 2020

ALK-Abelló and X-Chem Announce Drug Discovery Collaboration

WALTHAM, Mass. – February 5, 2019 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with ALK-Abelló A/S (ALK), a Danish pharmaceutical company focused on the prevention and treatment […]

Continue Reading
January 13, 2020

ZebiAI Therapeutics, Inc. and X-Chem Enter into Strategic Agreement to Enable Validation of Novel Therapeutic Targets and Acceleration of Drug Candidate Discovery

New venture capital-backed artificial intelligence company to utilize X-Chem’s leading DNA encoded library screening service WALTHAM, Mass. – ZebiAI Therapeutics, Inc. and X-Chem, Inc., both of Waltham, MA, and privately held companies, today announced a multiyear service and license agreement. The agreement provides ZebiAI access to X-Chem’s proprietary DNA Encoded Library technology (DEX™) for the […]

Continue Reading
September 4, 2019

Maruho and X-Chem Announce Drug Discovery Collaboration

WALTHAM, Mass. – September 4, 2019 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Maruho Co., Ltd. (Maruho) to discover lead compounds for novel and challenging targets […]

Continue Reading